company background image
OCGN logo

Ocugen NasdaqCM:OCGN Stock Report

Last Price

US$1.42

Market Cap

US$391.2m

7D

-11.3%

1Y

176.5%

Updated

14 Jun, 2024

Data

Company Financials +

OCGN Stock Overview

A clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health.

OCGN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Ocugen, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Ocugen
Historical stock prices
Current Share PriceUS$1.42
52 Week HighUS$2.11
52 Week LowUS$0.34
Beta3.8
1 Month Change-27.55%
3 Month Change31.48%
1 Year Change176.48%
3 Year Change-78.39%
5 Year Changen/a
Change since IPO-50.18%

Recent News & Updates

Recent updates

Ocugen announces peer-reviewed publication on COVID-19 vaccine

Sep 14

Ocugen initiated with Buy at Mizuho citing favorable setup ahead of key readout

Aug 23

Ocugen Q2 2022 Earnings Preview

Aug 04

Ocugen: A First Take

Jul 18

Ocugen in renewed focus as FDA wants COVID boosters to fight Omicron variant

Jul 05

Where Will Ocugen Stock Be In 5 Years?

Apr 27

Ocugen: FDA Lifts Clinical Hold As Shares Sink - It May Be Worth Staying The Course

Feb 24

Shareholder Returns

OCGNUS BiotechsUS Market
7D-11.3%0.2%1.2%
1Y176.5%7.4%20.5%

Return vs Industry: OCGN exceeded the US Biotechs industry which returned 7.4% over the past year.

Return vs Market: OCGN exceeded the US Market which returned 20.5% over the past year.

Price Volatility

Is OCGN's price volatile compared to industry and market?
OCGN volatility
OCGN Average Weekly Movement17.5%
Biotechs Industry Average Movement10.4%
Market Average Movement5.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.9%

Stable Share Price: OCGN's share price has been volatile over the past 3 months.

Volatility Over Time: OCGN's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201365Shankar Musunuriwww.ocugen.com

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult.

Ocugen, Inc. Fundamentals Summary

How do Ocugen's earnings and revenue compare to its market cap?
OCGN fundamental statistics
Market capUS$391.18m
Earnings (TTM)-US$57.68m
Revenue (TTM)US$6.61m

55.3x

P/S Ratio

-6.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
OCGN income statement (TTM)
RevenueUS$6.61m
Cost of RevenueUS$36.23m
Gross Profit-US$29.62m
Other ExpensesUS$28.06m
Earnings-US$57.68m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.22
Gross Margin-448.31%
Net Profit Margin-872.95%
Debt/Equity Ratio9.3%

How did OCGN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.